FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report third quarter 2017 financial results after the U.S. financial markets close on Thursday, November 2, 2017. Folowing the announcement, MyoKardia senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss these results and provide a business update.
Conference Call and Webcast
To access the live conference call, please dial 844-494-0193 (domestic) or 508-637-5584 (international) and refer to the conference ID 7295509.
The webcast may be accessed live on the Investor Relations section of the Company’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the call.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
Contact:
Michelle Corral MyoKardia, Inc.
650-351-4690
[email protected]
